Drug intelligence / Profile preview

Sonazyme

Development stage: Unknown
Lead developer: Skyways Healthcare
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Sonazyme is a digestive enzyme formulation developed and marketed by Skyways Healthcare. It is a combination product typically containing fungal diastase and pepsin, designed to assist in the breakdown of dietary components. Fungal diastase, an amylase enzyme derived from *Aspergillus oryzae*, facilitates the hydrolysis of complex carbohydrates (starch) into simpler sugars like maltose. Pepsin is a proteolytic enzyme that catalyzes the breakdown of proteins into smaller peptides. Sonazyme is primarily indicated for the relief of symptoms associated with indigestion, dyspepsia, flatulence, and abdominal distension. It is commonly available in oral liquid (syrup) and tablet forms within the Indian pharmaceutical market.

Brand names: Sonazyme
Other names: Fungal Diastase + Pepsin

Beyond the preview

Go deeper on Sonazyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sonazyme.

Explore the full profile